TCA
BSX icon

Transcend Capital Advisors’s Boston Scientific BSX Stock Holding History

Transcend Capital Advisors’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$854K Buy
13,616
+2,960
+28% +$237K 0.07% 263
2025
Q4 		$1.02M Sell
10,656
-2,973
-22% -$291K 0.08% 225
2025
Q3 		$1.33M Buy
13,629
+2,282
+20% +$236K 0.09% 198
2025
Q2 		$1.22M Buy
11,347
+2,638
+30% +$267K 0.09% 194
2025
Q1 		$879K Buy
8,709
+1,275
+17% +$128K 0.06% 273
2024
Q4 		$664K Buy
7,434
+271
+4% +$23.9K 0.05% 298
2024
Q3 		$600K Buy
7,163
+390
+6% +$30.7K 0.04% 350
2024
Q2 		$522K Buy
6,773
+148
+2% +$10.8K 0.04% 346
2024
Q1 		$454K Sell
6,625
-6,627
-50% -$426K 0.04% 346
2023
Q4 		$766K Buy
13,252
+1,084
+9% +$57.9K 0.07% 248
2023
Q3 		$642K Sell
12,168
-157
-1% -$8.23K 0.06% 257
2023
Q2 		$667K Buy
12,325
+7,956
+182% +$416K 0.06% 258
2023
Q1 		$219K Sell
4,369
-945
-18% -$44.5K 0.02% 431
2022
Q4 		$246K Buy
+5,314
New +$230K 0.03% 403
2022
Q2 		– Sell
-5,583
Closed -$247K – 503
2022
Q1 		$247K Buy
+5,583
New +$242K 0.02% 433

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Transcend Capital Advisors's BSX Position: Q1 2026 in Review

Transcend Capital Advisors increased its Boston Scientific (BSX) stake by 28% in Q1 2026, buying an estimated $237K and bringing the position to 13,616 shares worth $854K. The position accounts for 0.07% of the portfolio, ranked #263.

Transcend Capital Advisors first reported a position in BSX in Q1 2022 and has held it in 15 quarters since. The position peaked at $1.33M in Q3 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Transcend Capital Advisors held 13,616 shares of Boston Scientific worth $854K as of Q1 2026.
  • Transcend Capital Advisors bought 2,960 Boston Scientific shares in Q1 2026, an estimated $237K.
  • Boston Scientific made up 0.07% of Transcend Capital Advisors's portfolio in Q1 2026, its #263 holding.
  • Transcend Capital Advisors first reported a position in Boston Scientific in Q1 2022 and has held it in 15 quarters since.
  • Transcend Capital Advisors's Boston Scientific position peaked at $1.33M in Q3 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.